Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
TURKISH JOURNAL OF HEMATOLOGY, cilt.32, sa.2, ss.180-183, 2015 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32 Sayı: 2
- Basım Tarihi: 2015
- Doi Numarası: 10.4274/tjh.2013.0338
- Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.180-183
- Anahtar Kelimeler: Primary myelofibrosis, Ruxolitinib, Splenectomy, PATHOGENESIS, JAK2
- Ankara Üniversitesi Adresli: Evet
Özet
A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.